Comparison between a linear versus a macrocyclic contrast agent for whole body MR angiography in a clinical routine setting

Journal of Cardiovascular Magnetic Resonance

Volumn 10, Issue 1, 2008, Pages

  Seeger, Achim ^a   Kramer, Ulrich ^a   Fenchel, Michael ^a   Grimm, Florian ^a   Bretschneider, Christiane ^a   Döring, Jörg ^a   Klumpp, Bernhard ^a   Tepe, Gunnar ^a   Rittig, Kilian ^a   Seidensticker, Peter R ^b   Claussen, Claus D ^a   Miller, Stephan ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GADOBUTROL; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; IOPROMIDE; CONTRAST MEDIUM; DIAGNOSTIC AGENT; ORGANOMETALLIC COMPOUND;

AGED; ARTICLE; BLOOD VESSEL OCCLUSION; CLINICAL PRACTICE; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIGITAL SUBTRACTION ANGIOGRAPHY; FALSE NEGATIVE RESULT; FEMALE; HEMODYNAMICS; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; MAGNETIC RESONANCE ANGIOGRAPHY; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; ATHEROSCLEROSIS; CHEMICAL STRUCTURE; CHEMISTRY; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; RADIOGRAPHY; STENOSIS, OCCLUSION AND OBSTRUCTION; WHOLE BODY IMAGING;

AGED; ANGIOGRAPHY, DIGITAL SUBTRACTION; ATHEROSCLEROSIS; CONSTRICTION, PATHOLOGIC; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; MOLECULAR STRUCTURE; ORGANOMETALLIC COMPOUNDS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; WHOLE BODY IMAGING;

EID: 64549100301     PISSN: 10976647     EISSN: 1532429X     Source Type: Journal    
DOI: 10.1186/1532-429X-10-63     Document Type: Article

References (24)

1. Ross R: Atherosclerosis-an inflammatory disease. N Engl J Med 1999, 340:115-126.
2. Fenchel M, Requardt M, Tomaschko K, Kramer U, Stauder NI, Naegele T, Schlemmer HP, Claussen CD, Miller S: Whole-body MR angiography using a novel 32-receiving-channel MR system with surface coil technology: first clinical experience. J Magn ResonImaging 2005, 21:596-603. (Pubitemid 40586759)
3. Goyen M, Herborn CU, Kroger K, Ruehm SG, Debatin JF: Totalbody 3D magnetic resonance angiography influences the management of patients with peripheral arterial occlusive disease. Eur Radiol 2006, 16(3):685-691. (Pubitemid 44149381)
4. Kramer H, Schoenberg SO, Nikolaou K, Huber A, Struwe A, Winnik E, Wintersperger BJ, Dietrich O, Kiefer B, Reiser MF: Cardiovascular screening with parallel imaging techniques and a wholebody MR imager. Radiology 2005, 236:300-310. (Pubitemid 40853327)
5. Lin J, Chen B, Wang JH, Zeng MS, Wang YX: Whole-body threedimensional contrast-enhanced magnetic resonance (MR) angiography with parallel imaging techniques on a multichannel MR system for the detection of various systemic arterial diseases. Heart Vessels 2006, 21:395-398.
6. Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA: Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. AJR AmJ Roentgenol 2007, 188:586-592. (Pubitemid 46167763)
7. Sadowski EA, Bennett LK, Chan MR, Wentland AL, Garrett AL, Garrett RW, Djamali A: Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007, 243:148-157. (Pubitemid 46579705)
8. Emea : Public Assessment Report: Increased risk of nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis and gadolinium-containing MRI contrast agents. 2007 [http://www.esur.org/fileadmin/NSF/Public-Assessment-Report-NSF- Gadolinium-26-June-2007.pdf
9. Goyen M, Herborn CU, Vogt FM, Kroger K, Verhagen R, Yang F, Bosk S, Debatin JF, Ruehm SG: Using a 1 M Gd-chelate (gadobutrol) for total-body three-dimensional MR angiography: preliminary experience. J Magn ResonImaging 2003, 17:565-571. (Pubitemid 36528672)
10. Herborn CU, Goyen M, Quick HH, Bosk S, Massing S, Kroeger K, Stoesser D, Ruehm SG, Debatin JF: Whole-body 3D MR angiography of patients with peripheral arterial occlusive disease. AJR Am J Roentgenol 2004, 182(6):1427-1434. (Pubitemid 38668842)
11. Fenchel M, Scheule AM, Stauder NI, Kramer U, Tomaschko K, Nagele T, Bretschneider C, Schlemmer HP, Claussen CD, Miller S: Atherosclerotic disease: whole-body cardiovascular imaging with MR system with 32 receiver channels and total-body surface coil technology-initial clinical results. Radiology 2006, 238:280-291. (Pubitemid 43010606)
12. Klessen C, Asbach P, Hein PA, Lembcke A, Bauknecht HC, Huppertz A, Nentwig T, Hamm B, Taupitz M: [Whole-body MR angiography: comparison of two protocols for contrast media injection]. Rofo 2006, 178:484-490.
13. Schaefer FK, Schaefer PJ, Altjohann C, Bourne M, Decobelli F, Goyen M, Griffiths PD, Kopka L, Kreitner KF, Link J, et al.: A multicenter, site-independent, blinded study to compare the diagnostic accuracy of contrast-enhanced magnetic resonance angiography using 1.0M gadobutrol (Gadovist) to intraarterial digital subtraction angiography in body arteries. EurJ Radiol 2007, 61:315-323. (Pubitemid 46116786)
14. Goyen M, Lauenstein TC, Herborn CU, Debatin JF, Bosk S, Ruehm SG: 0.5 M Gd chelate (Magnevist) versus 1.0 M Gd chelate (Gadovist): dose-independent effect on image quality of pelvic three-dimensional MR-angiography. J Magn ResonImaging 2001, 14:602-607. (Pubitemid 33029547)
15. Tombach B, Benner T, Reimer P, Schuierer G, Fallenberg EM, Geens V, Wels T, Sorensen AG: Do highly concentrated gadolinium chelates improve MR brain perfusion imaging? Intraindividually controlled randomized crossover concentration comparison study of 0.5 versus 1.0 mol/L gadobutrol. Radiology 2003, 226:880-888. (Pubitemid 36259167)
16. Fink C, Puderbach M, Ley S, Risse F, Kuder TA, Bock M, Thaler J, Plathow C, Kauczor HU: Intraindividual comparison of 1.0 M gadobutrol and 0.5 M gadopentetate dimeglumine for timeresolved contrast-enhanced three-dimensional magnetic resonance angiography of the upper torso. J Magn ResonImaging 2005, 22:286-290. (Pubitemid 41045444)
17. Fink C, Puderbach M, Ley S, Plathow C, Bock M, Zuna I, Kauczor HU: Contrast-enhanced three-dimensional pulmonary perfusion magnetic resonance imaging: intraindividual comparison of 1.0 M gadobutrol and 0.5 M Gd-DTPA at three dose levels. Invest Radiol 2004, 39:143-148. (Pubitemid 38263920)
18. Fink C, Bock M, Kiessling F, Lichy MP, Krissak R, Zuna I, Schmahl A, Delorme S, Kauczor HU: Time-resolved contrast-enhanced three-dimensional pulmonary MR-angiography: 1.0 M gadobutrol vs. 0.5 M gadopentetate dimeglumine. J Magn ResonImaging 2004, 19:202-208. (Pubitemid 38166797)
19. Zhang H, Ho B, Mohajer K, Xu HJ: Peripheral magnetic resonance angiography with a multi-compartment curved leg wrap for thigh compression. J Cardiovasc Magn Reson 2007, 9:659-664 (Pubitemid 46956907)
20. Chiowanich P, Mitchell DG, Ortega HV, Mohamed F: Arterial pseudostenosis on first-pass gadolinium-enhanced three-dimensional MR angiography: new observation of a potential pitfall. AJR Am J Roentgenol 2000, 175(2):523-527. (Pubitemid 30619211)
21. Tombach B, Bremer C, Reimer P, Schaefer RM, Ebert W, Geens V, Heindel W: Pharmacokinetics of 1 M gadobutrol in patients with chronic renal failure. Invest Radiol 2000, 35:35-40. (Pubitemid 30033605)
22. Tombach B, Bremer C, Reimer P, Kisters K, Schaefer RM, Geens V, Heindel W: Renal tolerance of a neutral gadolinium chelate (gadobutrol) in patients with chronic renal failure: results of a randomized study. Radiology 2001, 218:651-657. (Pubitemid 32172543)
23. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, Salem DN, Levey AS, Sarnak MJ: Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol 2004, 15(5):1307-1315. (Pubitemid 38526012)
24. Reeder SB, Wintersperger BJ, Dietrich O, Lanz T, Greiser A, Reiser MF, Glazer GM, Schoenberg SO: Practical approaches to the evaluation of signal-to-noise ratio performance with parallel imaging: application with cardiac imaging and a 32-channel cardiac coil. Magn ResonMed 2005, 54:748-754. (Pubitemid 41233774)